About   Help   FAQ
Gene Ontology Classifications
Symbol
Name
ID
Snca
synuclein, alpha
MGI:1277151

Go Annotations as Summary Text (Tabular View) (GO Graph)

GO curators for mouse genes have assigned the following annotations to the gene product of Snca. (This text reflects annotations as of Thursday, January 16, 2014.) MGI curation of this mouse gene is considered complete, including annotations derived from the biomedical literature as of September 9, 2008. If you know of any additional information regarding this mouse gene please let us know. Please supply mouse gene symbol and a PubMed ID.
Summary from NCBI RefSeq


[Summary is not available for the mouse gene. This summary is for the human ortholog.] Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]
Summary text based on GO annotations supported by experimental evidence in mouse
Summary text based on GO annotations supported by experimental evidence in other organisms
Summary text for additional MGI annotations
References
  1. Abeliovich A et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25:239-52. (PubMed:10707987)
  2. Austin SA et al. (2006) Alpha-synuclein expression modulates microglial activation phenotype. J Neurosci, 26:10558-63. (PubMed:17035541)
  3. Barcelo-Coblijn G et al. (2007) Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. J Neurochem, 101:132-41. (PubMed:17250686)
  4. Bellucci A et al. (2011) Redistribution of DAT/alpha-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease. PLoS One, 6:e27959. (PubMed:22163275)
  5. Ben Gedalya T et al. (2009) Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic, 10:218-34. (PubMed:18980610)
  6. Cabin DE et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci, 22:8797-807. (PubMed:12388586)
  7. Chandra S et al. (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell, 123:383-96. (PubMed:16269331)
  8. Chandra S et al. (2004) Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A, 101:14966-71. (PubMed:15465911)
  9. Duka T et al. (2006) Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J, 20:2302-12. (PubMed:17077307)
  10. Ellis CE et al. (2005) Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol Cell Biol, 25:10190-201. (PubMed:16260631)
  11. Golovko MY et al. (2005) Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. Biochemistry, 44:8251-9. (PubMed:15938614)
  12. Golovko MY et al. (2006) Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism. Biochemistry, 45:6956-66. (PubMed:16734431)
  13. Greten-Harrison B et al. (2010) alphabetagamma-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A, 107:19573-8. (PubMed:20974939)
  14. Gureviciene I et al. (2007) Role of alpha-synuclein in synaptic glutamate release. Neurobiol Dis, 28:83-9. (PubMed:17689254)
  15. Kahle PJ et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain J Neurosci, 20:6365-73. (PubMed:10964942)
  16. Klivenyi P et al. (2006) Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis, 21:541-8. (PubMed:16298531)
  17. Kontopoulos E et al. (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet, 15:3012-23. (PubMed:16959795)
  18. Liu S et al. (2007) Alpha-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII. Eur J Neurosci, 25:3583-96. (PubMed:17610578)
  19. Liu S et al. (2004) alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J, 23:4506-16. (PubMed:15510220)
  20. Martin ED et al. (2004) Stressor-related impairment of synaptic transmission in hippocampal slices from alpha-synuclein knockout mice. Eur J Neurosci, 20:3085-91. (PubMed:15579163)
  21. Nakai M et al. (2007) Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage. Biochem Biophys Res Commun, 358:104-10. (PubMed:17475220)
  22. Qureshi HY et al. (2011) Parkinsonian Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and {alpha}-Synuclein Mutations Promote Tau Protein Phosphorylation at Ser262 and Destabilize Microtubule Cytoskeleton in Vitro. J Biol Chem, 286:5055-68. (PubMed:21127069)
  23. Rochet JC et al. (2000) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry, 39:10619-26. (PubMed:10978144)
  24. Sato S et al. (2006) 14-3-3eta is a novel regulator of parkin ubiquitin ligase. EMBO J, 25:211-21. (PubMed:16096643)
  25. Senior SL et al. (2008) Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur J Neurosci, 27:947-57. (PubMed:18333965)
  26. Sharon R et al. (2003) Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem, 278:49874-81. (PubMed:14507911)
  27. Stanic AK et al. (2006) Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci U S A, 103:7018-23. (PubMed:16636270)
  28. Tong Y et al. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of {alpha}-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A, 107:9879-84. (PubMed:20457918)



Go Annotations in Tabular Form (Text View) (GO Graph)

 
 


Gene Ontology Evidence Code Abbreviations:

  EXP Inferred from experiment
  IC Inferred by curator
  IDA Inferred from direct assay
  IEA Inferred from electronic annotation
  IGI Inferred from genetic interaction
  IMP Inferred from mutant phenotype
  IPI Inferred from physical interaction
  ISS Inferred from sequence or structural similarity
  ISO Inferred from sequence orthology
  ISA Inferred from sequence alignment
  ISM Inferred from sequence model
  NAS Non-traceable author statement
  ND No biological data available
  RCA Reviewed computational analysis
  TAS Traceable author statement


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
04/15/2014
MGI 5.17
The Jackson Laboratory